Defiance Nasdaq Junior Biotechnology ETF
IBBJ
IBBJ was delisted on the 2nd of December, 2021.
6 hedge funds and large institutions have $1.19M invested in Defiance Nasdaq Junior Biotechnology ETF in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
2,196% more capital invested
Capital invested by funds: $52K → $1.19M (+$1.14M)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
200% more funds holding
Funds holding: 2 → 6 (+4)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$718K |
| 2 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$257K |
| 3 |
IF
Ironwood Financial
Tucson,
Arizona
|
+$22.1K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$21.5K |
| 5 |
RWB
RMR Wealth Builders
Montclair,
New Jersey
|
+$12.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$24K |
| 2 |
EIP
Ellis Investment Partners
Berwyn,
Pennsylvania
|
-$767 |
IBBJ Hedge Fund Activity: Q4 2020 in Review
6 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Defiance Nasdaq Junior Biotechnology ETF (IBBJ) for Q4 2020, worth a combined $1.19M — up 2,196% from $52K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IBBJ positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $718K. The largest seller was UBS Group, exiting entirely with an estimated $24K sold.
- 6 institutional investors held Defiance Nasdaq Junior Biotechnology ETF (IBBJ) as of Q4 2020, up from 2 in Q3 2020.
- Funds reported $1.19M of Defiance Nasdaq Junior Biotechnology ETF stock for Q4 2020, up 2,196% quarter-over-quarter.
- 5 funds opened new Defiance Nasdaq Junior Biotechnology ETF positions in Q4 2020 and 1 closed out, a net change of +4 holders.
- The largest Defiance Nasdaq Junior Biotechnology ETF buyer in Q4 2020 was Tower Research Capital (TRC), an estimated $718K added.
- The largest Defiance Nasdaq Junior Biotechnology ETF seller in Q4 2020 was UBS Group, an estimated $24K sold.
Based on aggregated 13F filings for Q4 2020.